Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.

Twist Bioscience specializes in synthetic DNA production, providing gene fragments, next generation sequencing (NGS) tools, and antibody discovery platforms to research, diagnostic, pharmaceutical, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended ...

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the ...

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.

Twist Bioscience Corp. (NASDAQ:TWST) is one of the best emerging technology stocks to buy right now. The company manufactures synthetic DNA using a silicon-based synthesis platform, enabling scalable ...

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.